Alicia Levey is Chief Business Officer at Tempest Therapeutics, as well as an Operating Principal at Versant. Alicia previously led business development and alliance management activities across companies under the Inception Sciences umbrella. While at Inception, Alicia led or played key roles in new company incubation efforts and in establishing multiple enabling Pharma partnerships.
Prior to Inception, Alicia was a Principal in the San Francisco office of Versant where she led the diligence on multiple deals including several that have been acquired (Novira) or are now public (Audentes). Before joining Versant, Alicia worked as a Project Leader in the San Francisco office of The Boston Consulting Group where she primarily focused on biopharma and global health strategy. Alicia’s academic background is in Cancer Biology, earning a PhD from the Stanford University School of Medicine where she focused on the development of novel activity based protease probes for non-invasive imaging in cancer, work that led to multiple peer reviewed publications and two US patents. Originally from Colorado, Alicia graduated Summa Cum Laude with dual degrees in Molecular Biology and Biochemistry from the University of Colorado at Boulder where she was a Boettcher and Norlin Scholar.